Plasma cell proliferation index (PCPI) can help predict overall survival in people with newly diagnosed multiple myeloma, according to a study involving 151 individuals. Furthermore, it enables broader use of multiple myeloma cell proliferation for categorizing risk. Investigators grouped participants based on low (n=87) and high (n=64) myeloma cell proliferation. Using a plasma cell-specific biomarker, they evaluated how well multiplex immunohistochemistry calculated a PCPI. Among the results:
- Median overall survival was not reached in the low PCPI group, vs ~79 months in the high PCPI group.
- Only high-risk cytogenetics, ISS stage >I, and PCPI >5 independently impacted overall survival.
- 36% of patients with low risk disease were re-identified as high risk by PCPI.
Ely S, Forsberg P, Ouansafi I, et al. Cellular proliferation by multiplex immunohistochemistry identifies high risk multiple myeloma in newly diagnosed, treatment naïve patients. [Published online ahead of print September 19, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.010.
This Week's Must Reads
Policy statement on access to opioid medications, Statement on Opioid Use in Patients with Hematologic Diseases and Disorders, American Society of Hematology
FDA approves Mircera for dialysis-related anemia in pediatric patients, FDA approved-drug notice, June 7, 2018; Mircena label (Drugs@FDA)
FDA approves pembrolizumab for relapsed/refractory PMBCL, FDA Press Announcement, June 15, 2018; Keytruda Prescribing Information (Drugs@FDA)
Poor adherence to DOAC therapy requires attention, Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.
Red cell tranfusion may increase risk of postsurgical VTE, Goel R et al. JAMA Surg. 2018 Jun 13. doi: 10.1001/jamasurg.2018.1565
Must Reads in Multiple Myeloma
Ruxolitinib add-on boosted myeloma response, Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.
Refractory myeloma may respond to ruxolitinib add-on, Berenson JR, et al. J Clin Oncol 36, 2018 (suppl; abstr 8005).
Add-on ibrutinib boosted response in relapsed multiple myeloma, Chari A et al. Leuk Lymphoma. 2018 Apr 4. doi: 10.1080/10428194.2018.1443337.
Myeloma more likely to go untreated in dual Medicare-Medicaid recipients, Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.
In myeloma, go for a third transplant, Garderet L et al. Biol Blood Marrow Transplant. 2018 Feb 3. doi: 10.1016/j.bbmt.2018.01.035